

```

* * * * *
*           W E L C O M E   T O   T H E           *
*           U . S .   P A T E N T   T E X T   F I L E           *
* * * * *

```

=> s (interleukin-11 or IL-11)

```

      4847 INTERLEUKIN
      1720475 11
      74 INTERLEUKIN-11
        (INTERLEUKIN(W)11)
      12525 IL
      1720475 11
      178 IL-11
        (IL(W)11)
L1      201 (INTERLEUKIN-11 OR IL-11)

```

=> s 11 (p) (treat? or method? or therap? or administ?0

UNMATCHED LEFT PARENTHESIS 'P) (TREAT?'

=> s 11 (p) (treat? or method? or therap? or administ?)

```

      565326 TREAT?
      1268486 METHOD?
      83996 THERAP?
      111733 ADMINIST?
L2      108 L1 (P) (TREAT? OR METHOD? OR THERAP? OR ADMINIST?)

```

=> s 12 (p) (antibiotic?)

```

      29139 ANTIBIOTIC?
L3      4 L2 (P) (ANTIBIOTIC?)

```

=> d 13 1-4 kwic

US PAT NO: 5,700,664 [IMAGE AVAILABLE] L3: 1 of 4

DETDESC:

DETD(3)

Mammalian **IL-11** was initially isolated from a primate cell line developed by placing bone marrow cells from a healthy macaque monkey in. . . term culture and infecting them with the retrovirus U19-5 [Dr. Roger Cone, Tufts Medical School]. After incubation with the appropriate **antibiotic**, a live cell line designated PU34 was selected for its growth characteristics and induced with IL-1 alpha expressed in E. . . . A cDNA library was prepared from IL-1-stimulated (2u/ml IL-1 for 24 hours) PU34 cell mRNA according to the expression cloning **method** previously described in, e.g., G. G. Wong et al, Science, 228:810-815 (1985); Y. C. Yang et al, Cell, 47:3-10 (1986);. . .

US PAT NO: 5,679,339 [IMAGE AVAILABLE] L3: 2 of 4

SUMMARY:

BSUM(41)

Provided by the present invention are **methods** for using **IL-11** for the **treatment** of AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), **antibiotic** induced diarrheal diseases (Clostridium difficile), multiple sclerosis, osteoporosis, gingivitis, peptic ulcer disease, esophagitis, diabetes, retinitis, uveitis, reperfusion injury after myocardial. . .

SUMMARY:

BSUM(50)

The present invention thus involves **treating** patients having disorders such as AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), **antibiotic** induced diarrheal diseases (Clostridium difficile), multiple sclerosis, osteoporosis, gingivitis, peptic ulcer disease, esophagitis, diabetes, retinitis, uveitis, reperfusion injury after myocardial. . . atherosclerosis (plaque rupture), prevention of minor metastases, asthma, preeclampsia, and allergic disorders such as rhinitis, conjunctivitis, and urticaria and involves **administering** an effective amount of **IL-11** in a pharmaceutical carrier. **Treatment** is preferably prophylactic, but may also be at the onset of symptoms associated with the aforementioned disorders.

SUMMARY:

BSUM(55)

The following examples illustrate the **methods** of the present invention and in particular the use of **IL-11** in **treating** AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), **antibiotic** induced diarrheal diseases (Clostridium difficile), multiple sclerosis, osteoporosis, gingivitis, peptic ulcer disease, esophagitis, diabetes, retinitis, uveitis, reperfusion injury after myocardial. . .

US PAT NO: 5,371,193 [IMAGE AVAILABLE] L3: 3 of 4

DETDESC:

DETD(3)

Mammalian **IL-11** was initially isolated from a primate cell line developed by placing bone marrow cells from a healthy macaque monkey in. . . term culture and infecting them with the retrovirus U19-5 [Dr. Roger Cone, Tufts Medical School]. After incubation with the appropriate **antibiotic**, a live cell line designated PU34 was selected for its growth characteristics and induced with IL-1 alpha expressed in E. . . cDNA library was prepared from IL-1-stimulated (2 u/ml IL-1 for 24 hours) PU34 cell mRNA according to the expression cloning **method** previously described in, e.g., G. G. Wong et al, Science, 228:810-815 (1985); Y. C. Yang et al, Cell, 47:3-10 (1986);. . .

US PAT NO: 5,215,895 [IMAGE AVAILABLE] L3: 4 of 4

DETDESC:

DETD(3)

Mammalian **IL-11** was initially isolated from a primate cell line developed by placing bone marrow cells from a healthy macaque monkey in. . . term culture and infecting them with the retrovirus U19-5 [Dr. Roger Cone, Tufts Medical School]. After incubation with the appropriate **antibiotic**, a live cell line designated PU34 was selected for its

growth characteristics and induced with IL-1 alpha expressed in E. coli. A cDNA library was prepared from IL-1-stimulated (100 ng/ml IL-1 for 24 hours) PU34 cell mRNA according to the expression cloning **method** previously described in, e.g., G. G. Wong et al, Science, 228:810-815 (1985); Y. C. Yang et al, Cell, 47:3-10 (1986);. . .

=> d 13 1-4 cit

1. 5,700,664, Dec. 23, 1997, Mammalian cytokine, IL-11; Yu-Chung Yang, et al., 435/69.52; 424/85.2; 435/71.1, 252.3, 320.1; 530/351; 536/23.1, 23.5 [IMAGE AVAILABLE]

2. 5,679,339, Oct. 21, 1997, Method of using IL-11 for treating spondyloarthropies; James Keith, et al., 424/85.2; 530/351 [IMAGE AVAILABLE]

3. 5,371,193, Dec. 6, 1994, Mammalian cytokine, IL-11; Frances K. Bennett, et al., 530/351; 424/85.1; 435/69.52; 930/141 [IMAGE AVAILABLE]

4. 5,215,895, Jun. 1, 1993, DNA encoding a mammalian cytokine, interleukin-11; Frances K. Bennett, et al., 435/69.52, 69.5, 243, 252.3, 320.1, 365.1; 536/23.5 [IMAGE AVAILABLE]